On this page
Menkes disease
This severe genetic condition primarily impacts males, leading to copper deficiency in critical tissues like the brain. It typically causes significant neurological decline and developmental challenges from early infancy, affecting multiple body systems.
Available at Jeen Health
Clinical tests that include this
Overview
Menkes disease is a rare and severe genetic condition that affects the body's ability to properly absorb and transport copper. Copper is an essential trace mineral involved in many crucial bodily functions, including brain development, bone formation, and hair structure [PMID:33671077]. Without sufficient copper, these processes cannot function correctly.
This disorder is typically identified in early infancy, often around two to three months of age, when developmental delays and other distinctive symptoms become apparent. The condition progresses rapidly, leading to significant health complications. Because copper is essential for many enzymes, a deficiency can have widespread effects on health.
Menkes disease is considered a severe neurodegenerative disorder. While it affects males predominantly, females can be carriers and, in rare instances, may show milder symptoms. The exact prevalence of Menkes disease is not well established, but estimates suggest it affects approximately 1 in 100,000 to 250,000 males globally.
Symptoms & clinical features
The symptoms of Menkes disease often become noticeable between two and three months of age, following a period of apparently normal development after birth. One of the earliest and most characteristic signs is hair that is sparse, coarse, tangled, and brittle, often described as 'steely' or 'kinky' hair, and typically light in colour [PMID:33671077].
Neurological symptoms are prominent and severe. Infants may experience developmental delays, losing previously acquired skills (developmental regression), muscle weakness (hypotonia), and seizures that can be difficult to control. Other neurological features can include poor head control and a lack of responsiveness to their environment. Feeding difficulties, failure to thrive, and frequent vomiting are also commonly observed.
Further physical signs can include peculiar facial features, such as pale skin and full cheeks, as well as problems with bone development, leading to skeletal abnormalities. Bladder diverticula (pouches in the bladder wall) and blood vessel issues, such as twisted and narrowed arteries, may also occur, potentially leading to ruptures [PMID:20301418].
Video: Genetics 101
Affected organs
Menkes disease affects multiple organ systems throughout the body due to the widespread role of copper. The brain is profoundly impacted, leading to significant neurodegeneration. This results in severe developmental delays, intellectual disability, and uncontrolled seizures.
Connective tissues throughout the body are also affected, including those in the skin, hair, bones, and blood vessels. The characteristic 'steely' hair is a direct result of copper deficiency affecting hair structure. Bone abnormalities can include fragile bones and fractures. The integrity of blood vessels can be compromised, particularly arteries, making them prone to weakening and rupture. The gastrointestinal system may also be involved, contributing to feeding difficulties and poor nutrient absorption.
Risks & severity
Menkes disease is a severe and progressive condition. The prognosis is generally poor, with most affected individuals experiencing significant neurological decline from early infancy. The disease typically leads to profound developmental delays and severe intellectual disability. Seizures are common and can be challenging to manage, significantly impacting quality of life.
Individuals with Menkes disease often face a range of complications, including recurrent infections, feeding difficulties, and respiratory problems. The impaired blood vessel integrity can lead to serious internal bleeding. Without treatment, the condition is usually life-limiting, with many children not surviving beyond three years of age [PMID:20301418]. Early diagnosis and treatment with copper replacement therapy may improve outcomes for some individuals, though the overall severity remains high.
Genetic causes
Menkes disease is caused by pathogenic variants in the *ATP7A* gene. This gene provides instructions for making a protein called a copper-transporting ATPase. This protein is essential for moving copper within and between cells, playing a critical role in maintaining the body's copper balance [PMID:36577319]. Normally, the ATP7A protein is responsible for absorbing copper from the diet in the gut and distributing it to various tissues where it is needed, particularly the brain.
When a pathogenic variant occurs in *ATP7A*, the ATP7A protein may be non-functional or produced in insufficient amounts. This prevents cells from properly absorbing and distributing copper. As a result, copper accumulates in some tissues, such as the intestinal cells, while other critical organs, like the brain and liver, become severely copper-deficient. This deficiency in vital copper-dependent enzymes leads to the diverse and severe symptoms observed in Menkes disease.
- ATP7A ATPase copper transporting alphaThe ATP7A gene encodes a protein vital for regulating copper levels in the body, playing a key role in its absorption and distribution to various enzymes.
Inheritance pattern
Menkes disease follows an X-linked recessive inheritance pattern. This means the *ATP7A* gene is located on the X chromosome, one of the two sex chromosomes.
Males have one X chromosome and one Y chromosome (XY). If a male inherits an X chromosome with a pathogenic *ATP7A* variant, he will develop Menkes disease because he only has one copy of the gene. Females have two X chromosomes (XX). If a female inherits one X chromosome with a pathogenic *ATP7A* variant, she is typically a carrier and usually does not show severe symptoms because her other normal X chromosome can compensate. However, some female carriers may experience mild symptoms, such as steely hair or mild learning difficulties. A female carrier has a 50% chance with each pregnancy of passing the pathogenic variant to her children. Sons who inherit the variant will have Menkes disease, and daughters who inherit it will be carriers.
X-linked recessive: sons of a carrier mother have a 50% chance of being affected. Daughters have a 50% chance of being carriers.
Diagnosis & testing
The diagnosis of Menkes disease is typically suspected based on an infant's clinical symptoms, such as developmental regression, seizures, and the characteristic 'steely' hair. Blood tests showing abnormally low levels of copper and ceruloplasmin (a copper-carrying protein) can support the clinical suspicion. Further biochemical testing might reveal elevated levels of certain neurotransmitters in the cerebrospinal fluid [PMID:33671077].
Definitive diagnosis is confirmed through genetic testing, which involves analysing the *ATP7A* gene for pathogenic variants. This can be performed via a blood sample. For patients in the UK, such testing typically falls under the NHS Genomic Medicine Service (GMS) pathways, often referred through clinical genetics services. Relevant testing for this condition may be covered by an R-code, such as R253 for intellectual disability or R256 for developmental disorders, depending on the presenting features. A referral to a clinical geneticist or a paediatric neurologist would be the usual route for initiating diagnostic investigations.
Management & lifestyle
While there is no cure for Menkes disease, management focuses on supportive care and attempting to address the copper deficiency. Early diagnosis and intervention are critical. Copper replacement therapy, typically administered as subcutaneous injections of copper histidine, is the primary treatment [PMID:36577319]. This therapy aims to bypass the intestinal absorption defect and deliver copper directly to the bloodstream, where it can then be transported to other tissues.
Research suggests that copper replacement therapy, especially when started very early in life, ideally before symptoms become severe, can sometimes improve neurodevelopmental outcomes and extend life expectancy for some individuals [PMID:36577319]. However, the effectiveness can vary, and it does not reverse existing neurological damage. Symptomatic management includes anti-epileptic medications for seizures, physiotherapy and occupational therapy to support motor development, and nutritional support for feeding difficulties. Regular monitoring by a multidisciplinary team, including neurologists, geneticists, and dieticians, is essential. Genetic counsellors can also provide crucial support and information to families.
UK care pathway
In the UK, individuals suspected of having Menkes disease would typically be referred to specialist services within the NHS. This usually involves a paediatrician or general practitioner making a referral to a clinical genetics service or a paediatric neurology team. These specialist teams can then arrange for appropriate diagnostic genetic testing, which is part of the NHS Genomic Medicine Service (GMS). Genetic counsellors play a vital role in explaining the genetic basis of the condition, its inheritance pattern, and the implications for family members. They also provide emotional support and help families navigate the care pathway.
Frequently asked questions
What is the typical age for Menkes disease to be diagnosed?
Menkes disease symptoms usually become apparent between two and three months of age, following a brief period of normal development. Diagnosis is often confirmed soon after these symptoms appear, based on clinical signs, blood tests, and genetic testing.
Can females get Menkes disease?
Menkes disease primarily affects males because it is an X-linked recessive condition. Females are typically carriers and usually do not experience severe symptoms, though some may show mild features like distinctive hair or subtle developmental differences.
Is there a treatment for Menkes disease?
There is no cure for Menkes disease, but copper replacement therapy, administered via injections, is the main treatment. When started very early, this therapy can sometimes improve neurological outcomes and extend life expectancy, but it does not reverse existing damage.
What does 'steely hair' mean in Menkes disease?
Steely hair is a characteristic symptom of Menkes disease. It describes hair that is sparse, coarse, brittle, often tangled, and usually light in colour. This is due to the body's inability to properly incorporate copper into the hair structure.
How does Menkes disease affect the brain?
Menkes disease severely affects the brain because of a critical copper deficiency in brain tissue. This leads to progressive neurodegeneration, causing significant developmental delays, intellectual disability, and difficult-to-control seizures.
References
- Ramani PK, Parayil Sankaran B. Menkes Disease. 2023. PMID: 32809752
- Ashrafi MR, Ghasemi D, Safavi M. Menkes Disease. Archives of Iranian medicine. 2021. PMID: 35014241
- Vairo FPE, Chwal BC, Perini S. A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease. Molecular genetics and metabolism. 2019. PMID: 30594472
- Bertini I, Rosato A. Menkes disease. Cellular and molecular life sciences : CMLS. 2008. PMID: 17989919
- Miao KH, Yazdian Anari P, Mittal A. Menkes Disease. Radiographics : a review publication of the Radiological Society of North America, Inc. 2026. PMID: 42752239
- Kaler SG. Menkes disease. Advances in pediatrics. 1994. PMID: 7992686
- Gasch AT, Kaler SG, Kaiser-Kupfer M. Menkes disease. Ophthalmology. 1999. PMID: 10080197
- Tümer Z, Møller LB. Menkes disease. European journal of human genetics : EJHG. 2010. PMID: 19888294